img

Global OTC Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global OTC Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Non-prescription drugs refer to drugs that can be purchased for the convenience of the public without a prescription from a physician or other medical professional. The general public can use the drugs on their own discretion according to the drug labels and instructions.
Due to the COVID-19 pandemic, the global OTC Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Class A OTC Drug accounting for % of the OTC Drug global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The global key companies of OTC Drug include Bayer HealthCare, GlaxoSmithKline(GSK), Johnson&Johnson, Pfizer, Sanofi, AstraZeneca, BioGaia, Bristol Myers Squibb and Bukwang Pharmaceutica, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
The United States OTC Drug market size was US$ million in 2024, while China size was US$ million. The proportion of the United States was % in 2024, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe OTC Drug landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global OTC Drug market. The analysts authoring the report have closely studied key strategies adopted by top players of the global OTC Drug market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global OTC Drug market. Readers of the report can become informed about current and future trends of the global OTC Drug market and how they will impact market growth during the forecast period.



By Company


Bayer HealthCare
GlaxoSmithKline(GSK)
Johnson&Johnson
Pfizer
Sanofi
AstraZeneca
BioGaia
Bristol Myers Squibb
Bukwang Pharmaceutica
Chr. Hansen
Cipla
CoLucid
Daiichi Sankyo
Friggs
DSM
Eisai
Eli Lilly
Herbalife
Euradite
Segment by Type
Class A OTC Drug
Class B OTC Drug

Segment by Application


Hospital
Clinic
Household
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of OTC Drug in global and regional level.
Chapter 3Detailed analysis of OTC Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, OTC Drug revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global OTC Drug Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Class A OTC Drug
1.2.3 Class B OTC Drug
1.3 Market by Application
1.3.1 Global OTC Drug Market Growth Rate by Application: 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global OTC Drug Market Size (2018-2034)
2.2 OTC Drug Market Size across Key Geographies Worldwide: 2018 VS 2024 VS 2034
2.3 Global OTC Drug Market Size by Region (2018-2023)
2.4 Global OTC Drug Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 OTC Drug Countries Ranking by Market Size
3 OTC Drug Competitive by Company
3.1 Global OTC Drug Revenue by Players
3.1.1 Global OTC Drug Revenue by Players (2018-2023)
3.1.2 Global OTC Drug Market Share by Players (2018-2023)
3.2 Global OTC Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by OTC Drug Revenue
3.4 Global OTC Drug Market Concentration Ratio
3.4.1 Global OTC Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by OTC Drug Revenue in 2024
3.5 Global Key Players of OTC Drug Head office and Area Served
3.6 Global Key Players of OTC Drug, Product and Application
3.7 Global Key Players of OTC Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global OTC Drug Breakdown Data by Type
4.1 Global OTC Drug Historic Revenue by Type (2018-2023)
4.2 Global OTC Drug Forecasted Revenue by Type (2024-2034)
5 Global OTC Drug Breakdown Data by Application
5.1 Global OTC Drug Historic Market Size by Application (2018-2023)
5.2 Global OTC Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America OTC Drug Revenue by Company (2021-2023)
6.2 North America OTC Drug Revenue by Type (2018-2034)
6.3 North America OTC Drug Revenue by Application (2018-2034)
6.4 North America OTC Drug Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe OTC Drug Revenue by Company (2021-2023)
7.2 Europe OTC Drug Revenue by Type (2018-2034)
7.3 Europe OTC Drug Revenue by Application (2018-2034)
7.4 Europe OTC Drug Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific OTC Drug Revenue by Company (2021-2023)
8.2 Asia Pacific OTC Drug Revenue by Type (2018-2034)
8.3 Asia Pacific OTC Drug Revenue by Application (2018-2034)
8.4 Asia Pacific OTC Drug Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America OTC Drug Revenue by Company (2021-2023)
9.2 Latin America OTC Drug Revenue by Type (2018-2034)
9.3 Latin America OTC Drug Revenue by Application (2018-2034)
9.4 Latin America OTC Drug Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa OTC Drug Revenue by Company (2021-2023)
10.2 Middle East and Africa OTC Drug Revenue by Type (2018-2034)
10.3 Middle East and Africa OTC Drug Revenue by Application (2018-2034)
10.4 Middle East and Africa OTC Drug Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Bayer HealthCare
11.1.1 Bayer HealthCare Company Details
11.1.2 Bayer HealthCare Business Overview
11.1.3 Bayer HealthCare OTC Drug Products and Services
11.1.4 Bayer HealthCare OTC Drug Revenue in OTC Drug Business (2018-2023)
11.1.5 Bayer HealthCare OTC Drug SWOT Analysis
11.1.6 Bayer HealthCare Recent Development
11.2 GlaxoSmithKline(GSK)
11.2.1 GlaxoSmithKline(GSK) Company Details
11.2.2 GlaxoSmithKline(GSK) Business Overview
11.2.3 GlaxoSmithKline(GSK) OTC Drug Products and Services
11.2.4 GlaxoSmithKline(GSK) OTC Drug Revenue in OTC Drug Business (2018-2023)
11.2.5 GlaxoSmithKline(GSK) OTC Drug SWOT Analysis
11.2.6 GlaxoSmithKline(GSK) Recent Development
11.3 Johnson&Johnson
11.3.1 Johnson&Johnson Company Details
11.3.2 Johnson&Johnson Business Overview
11.3.3 Johnson&Johnson OTC Drug Products and Services
11.3.4 Johnson&Johnson OTC Drug Revenue in OTC Drug Business (2018-2023)
11.3.5 Johnson&Johnson OTC Drug SWOT Analysis
11.3.6 Johnson&Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer OTC Drug Products and Services
11.4.4 Pfizer OTC Drug Revenue in OTC Drug Business (2018-2023)
11.4.5 Pfizer OTC Drug SWOT Analysis
11.4.6 Pfizer Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi OTC Drug Products and Services
11.5.4 Sanofi OTC Drug Revenue in OTC Drug Business (2018-2023)
11.5.5 Sanofi OTC Drug SWOT Analysis
11.5.6 Sanofi Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca OTC Drug Products and Services
11.6.4 AstraZeneca OTC Drug Revenue in OTC Drug Business (2018-2023)
11.6.5 AstraZeneca OTC Drug SWOT Analysis
11.6.6 AstraZeneca Recent Development
11.7 BioGaia
11.7.1 BioGaia Company Details
11.7.2 BioGaia Business Overview
11.7.3 BioGaia OTC Drug Products and Services
11.7.4 BioGaia OTC Drug Revenue in OTC Drug Business (2018-2023)
11.7.5 BioGaia OTC Drug SWOT Analysis
11.7.6 BioGaia Recent Development
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Details
11.8.2 Bristol Myers Squibb Business Overview
11.8.3 Bristol Myers Squibb OTC Drug Products and Services
11.8.4 Bristol Myers Squibb OTC Drug Revenue in OTC Drug Business (2018-2023)
11.8.5 Bristol Myers Squibb OTC Drug SWOT Analysis
11.8.6 Bristol Myers Squibb Recent Development
11.9 Bukwang Pharmaceutica
11.9.1 Bukwang Pharmaceutica Company Details
11.9.2 Bukwang Pharmaceutica Business Overview
11.9.3 Bukwang Pharmaceutica OTC Drug Products and Services
11.9.4 Bukwang Pharmaceutica OTC Drug Revenue in OTC Drug Business (2018-2023)
11.9.5 Bukwang Pharmaceutica OTC Drug SWOT Analysis
11.9.6 Bukwang Pharmaceutica Recent Development
11.10 Chr. Hansen
11.10.1 Chr. Hansen Company Details
11.10.2 Chr. Hansen Business Overview
11.10.3 Chr. Hansen OTC Drug Products and Services
11.10.4 Chr. Hansen OTC Drug Revenue in OTC Drug Business (2018-2023)
11.10.5 Chr. Hansen OTC Drug SWOT Analysis
11.10.6 Chr. Hansen Recent Development
11.11 Cipla
11.11.1 Cipla Company Details
11.11.2 Cipla Business Overview
11.11.3 Cipla OTC Drug Products and Services
11.11.4 Cipla OTC Drug Revenue in OTC Drug Business (2018-2023)
11.11.5 Cipla Recent Development
11.12 CoLucid
11.12.1 CoLucid Company Details
11.12.2 CoLucid Business Overview
11.12.3 CoLucid OTC Drug Products and Services
11.12.4 CoLucid OTC Drug Revenue in OTC Drug Business (2018-2023)
11.12.5 CoLucid Recent Development
11.13 Daiichi Sankyo
11.13.1 Daiichi Sankyo Company Details
11.13.2 Daiichi Sankyo Business Overview
11.13.3 Daiichi Sankyo OTC Drug Products and Services
11.13.4 Daiichi Sankyo OTC Drug Revenue in OTC Drug Business (2018-2023)
11.13.5 Daiichi Sankyo Recent Development
11.14 Friggs
11.14.1 Friggs Company Details
11.14.2 Friggs Business Overview
11.14.3 Friggs OTC Drug Products and Services
11.14.4 Friggs OTC Drug Revenue in OTC Drug Business (2018-2023)
11.14.5 Friggs Recent Development
11.15 DSM
11.15.1 DSM Company Details
11.15.2 DSM Business Overview
11.15.3 DSM OTC Drug Products and Services
11.15.4 DSM OTC Drug Revenue in OTC Drug Business (2018-2023)
11.15.5 DSM Recent Development
11.16 Eisai
11.16.1 Eisai Company Details
11.16.2 Eisai Business Overview
11.16.3 Eisai OTC Drug Products and Services
11.16.4 Eisai OTC Drug Revenue in OTC Drug Business (2018-2023)
11.16.5 Eisai Recent Development
11.17 Eli Lilly
11.17.1 Eli Lilly Company Details
11.17.2 Eli Lilly Business Overview
11.17.3 Eli Lilly OTC Drug Products and Services
11.17.4 Eli Lilly OTC Drug Revenue in OTC Drug Business (2018-2023)
11.17.5 Eli Lilly Recent Development
11.18 Herbalife
11.18.1 Herbalife Company Details
11.18.2 Herbalife Business Overview
11.18.3 Herbalife OTC Drug Products and Services
11.18.4 Herbalife OTC Drug Revenue in OTC Drug Business (2018-2023)
11.18.5 Herbalife Recent Development
11.19 Euradite
11.19.1 Euradite Company Details
11.19.2 Euradite Business Overview
11.19.3 Euradite OTC Drug Products and Services
11.19.4 Euradite OTC Drug Revenue in OTC Drug Business (2018-2023)
11.19.5 Euradite Recent Development
12 OTC Drug Market Dynamics
12.1 OTC Drug Industry Trends
12.2 OTC Drug Market Drivers
12.3 OTC Drug Market Challenges
12.4 OTC Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global OTC Drug Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2024 VS 2034
Table 2. Key Players of Class A OTC Drug
Table 3. Key Players of Class B OTC Drug
Table 4. Global OTC Drug Market Size Growth Rate by Application (US$ Million), 2018 VS 2024 VS 2034
Table 5. Global OTC Drug Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2024 VS 2034
Table 6. Global OTC Drug Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global OTC Drug Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global OTC Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Table 9. Global OTC Drug Revenue by Players (2018-2023) & (US$ Million)
Table 10. Global OTC Drug Market Share by Players (2018-2023)
Table 11. Global Top OTC Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in OTC Drug as of 2024)
Table 12. Ranking of Global Top OTC Drug Companies by Revenue (US$ Million) in 2024
Table 13. Global 5 Largest Players Market Share by OTC Drug Revenue (CR5 and HHI) & (2018-2023)
Table 14. Global Key Players of OTC Drug, Headquarters and Area Served
Table 15. Global Key Players of OTC Drug, Product and Application
Table 16. Global Key Players of OTC Drug, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global OTC Drug Market Size by Type (2018-2023) & (US$ Million)
Table 19. Global OTC Drug Revenue Market Share by Type (2018-2023)
Table 20. Global OTC Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global OTC Drug Revenue Market Share by Type (2024-2034)
Table 22. Global OTC Drug Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global OTC Drug Revenue Market Share by Application (2018-2023)
Table 24. Global OTC Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global OTC Drug Revenue Market Share by Application (2024-2034)
Table 26. North America OTC Drug Revenue by Company (2021-2023) & (US$ Million)
Table 27. North America OTC Drug Revenue by Type (2018-2023) & (US$ Million)
Table 28. North America OTC Drug Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America OTC Drug Revenue by Application (2018-2023) & (US$ Million)
Table 30. North America OTC Drug Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America OTC Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 32. North America OTC Drug Revenue by Country (2018-2023) & (US$ Million)
Table 33. North America OTC Drug Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe OTC Drug Revenue by Company (2021-2023) & (US$ Million)
Table 35. Europe OTC Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Europe OTC Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe OTC Drug Revenue by Application (2018-2023) & (US$ Million)
Table 38. Europe OTC Drug Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe OTC Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 40. Europe OTC Drug Revenue by Country (2018-2023) & (US$ Million)
Table 41. Europe OTC Drug Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific OTC Drug Revenue by Company (2021-2023) & (US$ Million)
Table 43. Asia Pacific OTC Drug Revenue by Type (2018-2023) & (US$ Million)
Table 44. Asia Pacific OTC Drug Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific OTC Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Asia Pacific OTC Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific OTC Drug Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 48. Asia Pacific OTC Drug Revenue by Region (2018-2023) & (US$ Million)
Table 49. Asia Pacific OTC Drug Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America OTC Drug Revenue by Company (2021-2023) & (US$ Million)
Table 51. Latin America OTC Drug Revenue by Type (2018-2023) & (US$ Million)
Table 52. Latin America OTC Drug Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America OTC Drug Revenue by Application (2018-2023) & (US$ Million)
Table 54. Latin America OTC Drug Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America OTC Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 56. Latin America OTC Drug Revenue by Country (2018-2023) & (US$ Million)
Table 57. Latin America OTC Drug Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa OTC Drug Revenue by Company (2021-2023) & (US$ Million)
Table 59. Middle East and Africa OTC Drug Revenue by Type (2018-2023) & (US$ Million)
Table 60. Middle East and Africa OTC Drug Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa OTC Drug Revenue by Application (2018-2023) & (US$ Million)
Table 62. Middle East and Africa OTC Drug Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa OTC Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 64. Middle East and Africa OTC Drug Revenue by Country (2018-2023) & (US$ Million)
Table 65. Middle East and Africa OTC Drug Revenue by Country (2024-2034) & (US$ Million)
Table 66. Bayer HealthCare Company Details
Table 67. Bayer HealthCare Business Overview
Table 68. Bayer HealthCare OTC Drug Product and Services
Table 69. Bayer HealthCare OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 70. Bayer HealthCare OTC Drug SWOT Analysis
Table 71. Bayer HealthCare Recent Development
Table 72. GlaxoSmithKline(GSK) Company Details
Table 73. GlaxoSmithKline(GSK) Business Overview
Table 74. GlaxoSmithKline(GSK) OTC Drug Product and Services
Table 75. GlaxoSmithKline(GSK) OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 76. GlaxoSmithKline(GSK) OTC Drug SWOT Analysis
Table 77. GlaxoSmithKline(GSK) Recent Development
Table 78. Johnson&Johnson Company Details
Table 79. Johnson&Johnson Business Overview
Table 80. Johnson&Johnson OTC Drug Product and Services
Table 81. Johnson&Johnson OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 82. Johnson&Johnson OTC Drug SWOT Analysis
Table 83. Johnson&Johnson Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer OTC Drug Product and Services
Table 87. Pfizer OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 88. Pfizer OTC Drug SWOT Analysis
Table 89. Pfizer Recent Development
Table 90. Sanofi Company Details
Table 91. Sanofi Business Overview
Table 92. Sanofi OTC Drug Product and Services
Table 93. Sanofi OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 94. Sanofi OTC Drug SWOT Analysis
Table 95. Sanofi Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca OTC Drug Product and Services
Table 99. AstraZeneca OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 100. AstraZeneca OTC Drug SWOT Analysis
Table 101. AstraZeneca Recent Development
Table 102. BioGaia Company Details
Table 103. BioGaia Business Overview
Table 104. BioGaia OTC Drug Product and Services
Table 105. BioGaia OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 106. BioGaia OTC Drug SWOT Analysis
Table 107. BioGaia Recent Development
Table 108. Bristol Myers Squibb Company Details
Table 109. Bristol Myers Squibb Business Overview
Table 110. Bristol Myers Squibb OTC Drug Product and Services
Table 111. Bristol Myers Squibb OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 112. Bristol Myers Squibb OTC Drug SWOT Analysis
Table 113. Bristol Myers Squibb Recent Development
Table 114. Bukwang Pharmaceutica Company Details
Table 115. Bukwang Pharmaceutica Business Overview
Table 116. Bukwang Pharmaceutica OTC Drug Product and Services
Table 117. Bukwang Pharmaceutica OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 118. Bukwang Pharmaceutica OTC Drug SWOT Analysis
Table 119. Bukwang Pharmaceutica Recent Development
Table 120. Chr. Hansen Company Details
Table 121. Chr. Hansen Business Overview
Table 122. Chr. Hansen OTC Drug Product and Services
Table 123. Chr. Hansen OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 124. Chr. Hansen OTC Drug SWOT Analysis
Table 125. Chr. Hansen Recent Development
Table 126. Cipla Company Details
Table 127. Cipla Business Overview
Table 128. Cipla OTC Drug Product and Services
Table 129. Cipla OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 130. Cipla Recent Development
Table 131. CoLucid Company Details
Table 132. CoLucid Business Overview
Table 133. CoLucid OTC Drug Product and Services
Table 134. CoLucid OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 135. CoLucid Recent Development
Table 136. Daiichi Sankyo Company Details
Table 137. Daiichi Sankyo Business Overview
Table 138. Daiichi Sankyo OTC Drug Product and Services
Table 139. Daiichi Sankyo OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 140. Daiichi Sankyo Recent Development
Table 141. Friggs Company Details
Table 142. Friggs Business Overview
Table 143. Friggs OTC Drug Product and Services
Table 144. Friggs OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 145. Friggs Recent Development
Table 146. DSM Company Details
Table 147. DSM Business Overview
Table 148. DSM OTC Drug Product and Services
Table 149. DSM OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 150. DSM Recent Development
Table 151. Eisai Company Details
Table 152. Eisai Business Overview
Table 153. Eisai OTC Drug Product and Services
Table 154. Eisai OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 155. Eisai Recent Development
Table 156. Eli Lilly Company Details
Table 157. Eli Lilly Business Overview
Table 158. Eli Lilly OTC Drug Product and Services
Table 159. Eli Lilly OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 160. Eli Lilly Recent Development
Table 161. Herbalife Company Details
Table 162. Herbalife Business Overview
Table 163. Herbalife OTC Drug Product and Services
Table 164. Herbalife OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 165. Herbalife Recent Development
Table 166. Euradite Company Details
Table 167. Euradite Business Overview
Table 168. Euradite OTC Drug Product and Services
Table 169. Euradite OTC Drug Revenue in OTC Drug Business (2018-2023) & (US$ Million)
Table 170. Euradite Recent Development
Table 171. OTC Drug Market Trends
Table 172. OTC Drug Market Drivers
Table 173. OTC Drug Market Challenges
Table 174. OTC Drug Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. OTC Drug Product Picture
Figure 2. Global OTC Drug Market Size by Type (US$ Million): 2018 VS 2024 VS 2034
Figure 3. Global OTC Drug Market Share by Type: 2024 VS 2034
Figure 4. Class A OTC Drug Features
Figure 5. Class B OTC Drug Features
Figure 6. Global OTC Drug Market Size by Application (US$ Million): 2018 VS 2024 VS 2034
Figure 7. Global OTC Drug Market Share by Application: 2024 VS 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Household
Figure 11. OTC Drug Report Years Considered
Figure 12. Global OTC Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global OTC Drug Market Size 2018-2034 (US$ Million)
Figure 14. Global OTC Drug Market Size Market Share by Region: 2024 VS 2034
Figure 15. Global OTC Drug Revenue Market Share by Region in 2018 VS 2024
Figure 16. Global OTC Drug Revenue Market Share Forecast by Region (2024-2034)
Figure 17. Global Top 10 OTC Drug Countries Ranking by Market Size (US$ Million) in 2024
Figure 18. Global OTC Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Figure 19. Global OTC Drug Market Share by Players in 2024
Figure 20. Global Top OTC Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in OTC Drug as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by OTC Drug Revenue in 2024
Figure 22. North America OTC Drug Revenue Market Share by Company in 2024
Figure 23. North America OTC Drug Revenue Market Share by Type (2018-2034)
Figure 24. North America OTC Drug Revenue Market Share by Application (2018-2034)
Figure 25. North America OTC Drug Revenue Share by Country (2018-2034)
Figure 26. U.S. OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 27. Canada OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 28. Europe OTC Drug Revenue Market Share by Company in 2024
Figure 29. Europe OTC Drug Revenue Market Share by Type (2018-2034)
Figure 30. Europe OTC Drug Revenue Market Share by Application (2018-2034)
Figure 31. Europe OTC Drug Revenue Share by Country (2018-2034)
Figure 32. Germany OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 33. France OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 34. U.K. OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 35. Italy OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 36. Russia OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 37. Asia Pacific OTC Drug Revenue Market Share by Company in 2024
Figure 38. Asia Pacific OTC Drug Revenue Market Share by Type (2018-2034)
Figure 39. Asia Pacific OTC Drug Revenue Market Share by Application (2018-2034)
Figure 40. Asia Pacific OTC Drug Revenue Share by Region (2018-2034)
Figure 41. China OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 42. Japan OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 43. South Korea OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 44. India OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Australia OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Taiwan OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Indonesia OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Thailand OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Malaysia OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Philippines OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 51. Vietnam OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America OTC Drug Revenue Market Share by Company in 2024
Figure 53. Latin America OTC Drug Revenue Market Share by Type (2018-2034)
Figure 54. Latin America OTC Drug Revenue Market Share by Application (2018-2034)
Figure 55. Latin America OTC Drug Revenue Share by Country (2018-2034)
Figure 56. Mexico OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa OTC Drug Revenue Market Share by Company in 2024
Figure 60. Middle East and Africa OTC Drug Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa OTC Drug Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa OTC Drug Revenue Share by Country (2018-2034)
Figure 63. Turkey OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 65. U.A.E OTC Drug Revenue (2018-2034) & (US$ Million)
Figure 66. Bayer HealthCare Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 67. GlaxoSmithKline(GSK) Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 68. Johnson&Johnson Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 69. Pfizer Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 70. Sanofi Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 71. AstraZeneca Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 72. BioGaia Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 73. Bristol Myers Squibb Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 74. Bukwang Pharmaceutica Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 75. Chr. Hansen Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 76. Cipla Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 77. CoLucid Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 78. Daiichi Sankyo Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 79. Friggs Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 80. DSM Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 81. Eisai Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 82. Eli Lilly Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 83. Herbalife Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 84. Euradite Revenue Growth Rate in OTC Drug Business (2018-2023)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed